Hammad Muhammed A M, Miller Jake, Sultan Mark I, Abou Chawareb Elia, Nakamura Hana S, Martinez Juan R, Lumbiganon Supanut, Jenkins Lawrence, Barham David W, Bandaru Dhiresh, Yih Jessica M, Yafi Faysal A
Department of Urology, University of California, 20 palatine, Apt 216 in Villa Sienna, Irvine, CA 92612, USA.
Department of Urology, University of California, Irvine, Irvine, CA, USA.
Ther Adv Urol. 2025 Feb 24;17:17562872251322651. doi: 10.1177/17562872251322651. eCollection 2025 Jan-Dec.
The use of alternative treatment modalities for erectile dysfunction (ED) beyond phosphodiesterase inhibitors continues to grow within the practice of Urology. Utilizing U.S. Google trends as a novel epidemiological tool for geographically associating patient search intent, our study aims to capture trends relating to interest in stem cell therapy (SCT) as a potential treatment for ED.
An online search was conducted to identify centers in the United States offering stem cell therapy (SCT) for erectile dysfunction (ED), using specific keywords such as "ED treatment," "stem cells for ED," and "sexual health stem cell." The geographic distribution of these centers was mapped, and their publicly available information was evaluated based on strict inclusion criteria, including direct claims of SCT efficacy for ED and oversight by a licensed urologist. The public interest in SCT treatment was quantified using Google Trends data from July 2018 to July 2023, utilizing search terms related to SCT and comparing them to terms associated with alternative regenerative therapies like platelet-rich plasma and shockwave treatments, to extract the direction and magnitude of national interest over the preceding 5 years. The PubMed, Cochrane Library, and EMBASE databases were then searched from inception to May 2024 regarding evidence for the use of SCT to treat ED.
Despite insufficient evidence, public search interest demonstrates an upward trajectory of this treatment when compared to alternative regenerative therapies for ED. This increased interest in SCT as a potential treatment option for ED may be linked to the marketing efforts of commercial entities. Throughout the qualitative analysis of advertisement sources, only two websites (Stem Cells Transplant Institute, and Ambrose Cell Therapy) summarized the collective results of a directed clinical trial investigating the utility of SCT in ED patients.
Our study demonstrates the public prevalence of patients seeking SCT as a treatment modality for ED is increasing. In addition, varied sources nationwide promote SCT despite limited scientific evidence and consensus. This disparity calls for additional prospective research on the viability, efficacy, and long-term safety of SCT in the context of ED.
在泌尿外科实践中,除磷酸二酯酶抑制剂外,用于治疗勃起功能障碍(ED)的替代治疗方式的使用持续增加。利用美国谷歌趋势作为一种新颖的流行病学工具来将患者搜索意图与地理位置相关联,我们的研究旨在捕捉与对干细胞疗法(SCT)作为ED潜在治疗方法的兴趣相关的趋势。
进行在线搜索以确定美国提供用于勃起功能障碍(ED)的干细胞疗法(SCT)的中心,使用“ED治疗”、“用于ED的干细胞”和“性健康干细胞”等特定关键词。绘制这些中心的地理分布,并根据严格的纳入标准评估其公开可用信息,包括关于SCT对ED疗效的直接声明以及由持牌泌尿外科医生进行监督。使用2018年7月至2023年7月的谷歌趋势数据对SCT治疗的公众兴趣进行量化,利用与SCT相关的搜索词并将其与与富含血小板血浆和冲击波治疗等替代再生疗法相关的术语进行比较,以提取过去5年全国兴趣的方向和程度。然后从创刊到2024年5月在PubMed、Cochrane图书馆和EMBASE数据库中搜索关于使用SCT治疗ED的证据。
尽管证据不足,但与ED的替代再生疗法相比,公众搜索兴趣表明这种治疗呈上升趋势。对SCT作为ED潜在治疗选择的兴趣增加可能与商业实体的营销努力有关。在对广告来源的定性分析中,只有两个网站(干细胞移植研究所和安布罗斯细胞疗法)总结了一项针对SCT在ED患者中的效用的定向临床试验的综合结果。
我们的研究表明,寻求SCT作为ED治疗方式的患者在公众中越来越普遍。此外,尽管科学证据和共识有限,但全国范围内各种来源都在推广SCT。这种差异要求对SCT在ED背景下的可行性、疗效和长期安全性进行更多前瞻性研究。